Presentation is loading. Please wait.

Presentation is loading. Please wait.

Baseline Characteristics by hs-CRP

Published byΝαθάμ Ευταξίας Modified over 5 years ago

Similar presentations

Presentation on theme: "Baseline Characteristics by hs-CRP"— Presentation transcript:

1 Baseline Characteristics by hs-CRP
Marc S. Sabatine, et al. Circulation 2007;115:

2 Cumulative incidence curves for cardiovascular death, MI, or stroke by hs-CRP group
Marc S. Sabatine, et al. Circulation 2007;115:

3 Rate of cardiovascular death, MI, or stroke by hs-CRP group and treatment group Solid bars indicate patients randomized to placebo Striped bars, patients randomized to trandolapril Marc S. Sabatine, et al. Circulation 2007;115:

4 Association of hs-CRP with the risk of cardiovascular death, MI, or stroke in various subgroups
Marc S. Sabatine, et al. Circulation 2007;115:

5 Multivariable adjustment for the association of hs-CRP with the risk of cardiovascular death, MI, or stroke Marc S. Sabatine, et al. Circulation 2007;115:

6 Association of hs-CRP and Risk of Cardiovascular Death, MI, or Stroke
Marc S. Sabatine, et al. Circulation 2007;115:

7 Rate of new-onset heart failure (CHF) by
hs-CRP group and treatment group Solid bars indicate patients randomized to placebo Striped bars, patients randomized to trandolapril Marc S. Sabatine, et al. Circulation 2007;115:

8 Rate of new-onset diabetes by hs-CRP group and treatment group Solid bars indicate patients randomized to placebo Striped bars, patients randomized to trandolapril Marc S. Sabatine, et al. Circulation 2007;115:

Download ppt "Baseline Characteristics by hs-CRP"

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]
Trial profile Fox K et al. Lancet 2008;372:807-16.

Trial profile Fox K et al. Lancet 2008;372:
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol 5.5-8.0 Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.

PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.
Philip J. Barter, et al. Circulation 2011;124:555-562.

Philip J. Barter, et al. Circulation 2011;124:
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results www.shift-study.com Swedberg K, et al. Lancet. 2010;376(9744):875-885.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):
Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:1338- 1347.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,

TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
Solomon Tesfaye et al N Engl J Med 2005;352:341- 50 Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.
Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-72.

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:
Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.

Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Prognostic Value of B-Type Natriuretic Peptides in Patients with Stable Coronary Artery Disease The PEACE trial Omland T, et al. JACC 2007;50:205-14.

Prognostic Value of B-Type Natriuretic Peptides in Patients with Stable Coronary Artery Disease The PEACE trial Omland T, et al. JACC 2007;50:
Search strategy and results Amir Kashani, et al. Circulation. 2006;114:2788-2797.

Search strategy and results Amir Kashani, et al. Circulation. 2006;114:
Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.

Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.
The SPRINT Research Group

The SPRINT Research Group
Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:2123-2133.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Similar presentations

Ads by Google